Bone marrow: an extra-pancreatic hideout for the elusive pancreatic stem cell?

negative’ myasthenia gravis. J. Neuroimmunol. 28:83–93. 8. Drachman, D.B., de Silva, S., Ramsay, D., and Pestronk, A. 1987. Humoral pathogenesis of myasthenia gravis. Ann. NY Acad. Sci. 505:90–105. 9. Drachman, D., DeSilva, S., Ramsay, D., and Pestronk, A. 1987. “Sero-negative” myasthenia gravis: a humorally mediated variant of myasthenia. Neurology. 37(Suppl. 1):214. 10. Burges, J., et al. 1994. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve. 17:1393–1400. 11. Hoch, W., et al. 2001. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7:365–368. 12. Darnell, R.B. 1996. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. U. S. A. 93:4529–4236. 13. Schoepfer, R., Halvorsen, S.W., Conroy, W.G., Whiting, P., and Lindstrom, J. 1989. Antisera against an acetylcholine receptor alpha 3 fusion protein bind to ganglionic but not to brain nicotinic acetylcholine receptors. FEBS Lett. 257:393–399. 14. Xu, W., et al. 1999. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. U. S. A. 96:5746–5751. 15. Toyka, K.V., Drachman, D.B., Pestronk, A., and Kao, I. 1975. Myasthenia gravis: passive transfer from man to mouse. Science. 190:397–399. 16. Rose, N., and Mackay, I. 1998. The autoimmune diseases: prelude. In The autoimmune diseases. N. Rose and I. Mackay, editors. Academic Press. San Diego, California, USA. 1. 17. Drachman, D.B., et al. 2003. Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the “guided missile” strategy. Ann. N. Y. Acad. Sci. In press.